arrow
R

Roberta Di Blasi

universite paris cite
H指数:29
被引数:4,309

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

大B细胞淋巴瘤CAR T细胞疗法后的应答动力学:DESCAR-T登记研究中的LYSA研究

2026-08-210
PRE
Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR-T registry
2026-07-280
OAAI
Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study

CAR T细胞疗法期间复发/难治性弥漫大B细胞淋巴瘤的标准化FDG-PET解读:一项DESCAR-T研究

2026-07-250
PRE
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis

原发性纵隔B细胞淋巴瘤患者在CAR-T细胞疗法失败后的结局与治疗模式:一项DESCAR-T分析

2025-12-010
OAAI
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry

CD19 CAR T细胞疗法治疗B细胞淋巴瘤后的侵袭性真菌感染:一项来自DESCAR-T登记研究的LYSA研究

2025-10-160
OAAI
Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched Study

常规使用左乙拉西坦进行预防对LBCL的CD19 CAR-T治疗无益:一项多中心倾向性匹配研究

2025-08-110
OAAI
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

TRANSCAR:CD19 CAR T细胞疗法在复发/难治性转化型惰性淋巴瘤中的真实世界疗效

2025-05-050
OAAI
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry

复发或难治性原发纵隔B细胞淋巴瘤患者接受抗CD19 CAR-T细胞治疗的结局:CARTHYM,一项来自法国国家DESCAR-T登记研究的报告

2025-02-182
OAAI
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
2024-08-061
OAAI
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2024-07-230
OAAI
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
2024-06-202
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network

CAR T细胞疗法在复发性原发性中枢神经系统淋巴瘤中诱导高缓解率: LOC网络的现实结果

2024-04-087
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
2023-10-3023
OAAI